I’m pretty sure that this is related to competition for trial participants. There are currently two clinical studies in the US which are recruiting from the Angelman Syndrome population. Hoffman-La Roche commenced a 74 patient Phase 1 study in August 2020, which doesn’t complete until December next year. Also, Ultragenyx commenced an 83 patient Phase 1/2 study in February 2020 which isn't due to complete until next year.
Neuren’s decision to run the Angelman trial in Australia may also have been influenced by the fact that there are two active organisations here which are dedicated to supporting the Angelman Syndrome community - the Angelman Syndrome Association of Australia (ASAA) and the Foundation for Angelman Syndrome Therapeutics (FAST Australia). Both organisations provide support to families participating in clinical studies.
https://angelmansyndrome.org/research-2
https://cureangelman.org.au/neuren-australian-clinical-trial/
2591 upcoming trials, page-17
-
- There are more pages in this discussion • 3 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add NEU (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$16.15 |
Change
-0.940(5.50%) |
Mkt cap ! $2.064B | |||
| Open | High | Low | Value | Volume |
| $15.04 | $16.33 | $14.65 | $25.91M | 1.638M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 125 | $16.15 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $16.20 | 1500 | 1 |
View Market Depth
| Last trade - 16.10pm 09/08/2024 (20 minute delay) ? |
| NEU (ASX) Chart |